吡非尼酮治疗不可分类进展性纤维化间质性肺病:双盲随机安慰剂对照2期试验
这项多中心双盲随机安慰剂对照2期试验纳入253例进展性纤维化不可分类间质性肺病患者,评估吡非尼酮2403 mg/日与安慰剂的疗效和安全性。
要点
- 吡非尼酮组胃肠道不良事件更常见(47% vs 26%),严重不良事件两组相近。
核心结论
- 尽管主要终点预设统计模型未能应用,关键次要终点分析提示进展性纤维化不可分类间质性肺病患者可能从吡非尼酮治疗中获益,安全性和耐受性可接受。
研究设计与样本
- 多中心、双盲、随机、安慰剂对照2期试验,在澳大利亚、比利时、加拿大等14个国家70个中心进行。
- 纳入253例进展性纤维化不可分类间质性肺病患者,随机1:1接受吡非尼酮2403 mg/日(n=127)或安慰剂(n=126),治疗24周。
- 纳入标准包括年龄18-85岁、FVC预测值≥45%、DLco预测值≥30%、高分辨率CT纤维化>10%。
- 主要终点为家庭肺功能仪测量的24周FVC平均预测变化,因个体内变异未能应用预设统计模型。
- 疗效分析基于意向治疗人群,安全性分析基于至少接受一次研究药物的随机患者。
主要发现
- UCSD-SOBQ、莱斯特咳嗽问卷、咳嗽视觉模拟量表及SGRQ评分变化两组相似;急性加重、住院和呼吸相关死亡事件数少,未得出有意义的分析结果;无进展生存期两组无差异。
关键数值与推荐
- 吡非尼酮用法为2403 mg口服每日一次(原文为每日总量2403 mg,分次服用未详述)。
- 主要终点因家庭肺功能仪个体内变异未能应用预设统计模型。
临床怎么用
- 对于进展性纤维化不可分类间质性肺病患者,吡非尼酮可能减缓FVC下降,但需关注胃肠道不良反应。
- 家庭肺功能仪监测的个体内变异可能影响疗效评估,临床决策应结合多点肺功能测量。
- 治疗期间应监测FVC变化及不良反应,严重不良事件发生率两组相近。
局限性
- 主要终点预设统计模型未能应用,主要终点分析受影响。
- 急性加重、住院和呼吸相关死亡事件数少,相关分析未得出有意义的结论。
- 研究为2期试验,样本量253例,随访24周,长期疗效和安全性未确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: At present, no approved pharmacotherapies are available for unclassifiable interstitial lung disease (ILD), which is characterised by progressive fibrosis of the lung. We aimed to assess the efficacy and safety of pirfenidone in patients with progressive fibrosing unclassifiable ILD. METHODS: We did a multicentre, double-blind, randomised, placebo-controlled phase 2 trial at 70 centres in Australia, Belgium, Canada, Czech Republic, Denmark, Germany, Greece, Ireland, Israel, Italy, Poland, Portugal, Spain, and the UK. Eligible patients (aged ≥18-85 years) had progressive fibrosing unclassifiable ILD, a percent predicted forced vital capacity (FVC) of 45% or higher and percent predicted carbon monoxide diffusing capacity (DLco) of 30% or higher, more than 10% fibrosis on high-resolution CT, and a high-resolution CT from the previous 12 months. Patients were randomly assigned (1:1) to 2403 mg oral pirfenidone daily or placebo using a central validated interactive voice or web-based response system, stratified by concomitant mycophenolate mofetil use and presence or absence of interstitial pneumonia with autoimmune features. Investigators, site personnel, and patients were masked to treatment assignment. The primary endpoint was mean predicted change in FVC from baseline over 24 weeks, measured by daily home spirometry. Secondary endpoints were change in FVC measured by site spirometry, proportion of patients who had a more than 5% or more than 10% absolute or relative decline in percent predicted FVC measured by clinic-based spirometry, change in percent predicted DLco, change in 6-min walk distance (6MWD), change in University of California San Diego-Shortness of Breath Questionnaire (UCSD-SOBQ) score, change in Leicester Cough Questionnaire score, change in cough visual analogue scale, and changes in total and subscores of the St George's Respiratory Questionnaire (SGRQ), all of which were compared with baseline. Additional secondary endpoints included proportion of patients who had non-elective hospitalisation (respiratory and all-cause) and acute exacerbations, and progression-free survival. Efficacy was analysed in the intention-to-treat (ITT) population, which included all randomly assigned patients. Safety was assessed in the safety analysis set, which included all randomly assigned patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, NCT03099187, and is no longer recruiting. FINDINGS: Between May 15, 2017, and June 5, 2018, 253 patients were randomly assigned to receive 2403 mg pirfenidone (n=127) or placebo (n=126) and were included in the ITT analysis set. Analysis of the primary endpoint was affected by intraindividual variability in home spirometry values, which prevented application of the prespecified statistical model. Over 24 weeks, predicted median change in FVC measured by home spirometry was -87·7 mL (Q1-Q3 -338·1 to 148·6) in the pirfenidone group versus -157·1 mL (-370·9 to 70·1) in the placebo group. Over 24 weeks, predicted mean change in FVC measured by site spirometry was lower in patients given pirfenidone than placebo (treatment difference 95·3 mL [95% CI 35·9 to 154·6], p=0·002). Compared with the placebo group, patients in the pirfenidone group were less likely to have a decline in FVC of more than 5% (odds ratio [OR] 0·42 [95% CI 0·25 to 0·69], p=0·001) or more than 10% (OR 0·44 [0·23 to 0·84], p=0·011). At week 24, mean change in DLco from baseline was -0·7% (SD 7·1) for the pirfenidone group and -2·5% (8·8) for the placebo group, and mean change in 6MWD from baseline was -2·0 m (68·1) for the pirfenidone group and -26·7 m (79·3) for the placebo group. Changes from baseline in UCSD-SOBQ, Leicester Cough Questionnaire score, cough visual analogue scale, and SGRQ scores were similar between the pirfenidone and placebo groups at week 24. Analysis of acute exacerbations, hospital admissions, and time to death from respiratory causes during the study yielded no meaningful results due to a small number of events. No differences in progression-free survival were identified between the pirfenidone and placebo groups, irrespective of the definition of progression-free survival used. Treatment-emergent adverse events were reported in 120 (94%) of 127 patients in the pirfenidone group and 101 (81%) of 124 patients in the placebo group. Serious treatment-emergent adverse events were reported in 18 (14%) patients in the pirfenidone group and 20 (16%) patients in the placebo group. The most common treatment-related treatment-emergent adverse events were gastrointestinal disorders (60 [47%] in the pirfenidone group vs 32 [26%] in the placebo group), fatigue (16 [13%] vs 12 [10%]), and rash (13 [10%] vs nine [7%]). INTERPRETATION: Although the planned statistical model could not be applied to the primary endpoint data, analysis of key secondary endpoints suggests that patients with progressive fibrosing unclassifiable ILD could benefit from pirfenidone treatment, which has an acceptable safety and tolerability profile. These findings support further investigation of pirfenidone as an effective treatment for patients with progressive fibrotic unclassifiable ILD. FUNDING: F Hoffmann-La Roche.
引用
- Maher TM, Corte TJ, Fischer A, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2019. PMID: 31578169. doi:10.1016/S2213-2600(19)30341-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。